Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

13-year Follow-up of Women With Chronic Low Back Pain in Primary Care - a Prospective Longitudinal Cohort Study

25 maj 2026 uppdaterad av: Vastra Gotaland Region

Background: Low back pain (LBP) is among the main causes of long-term sickness absence and is associated with considerable costs for both the individual and society. LBP affects 60-80% of the population and most individuals recover, while about 10-20% develop persistent pain and disability. Women have a higher risk of developing chronic LBP (CLBP) and widespread pain.

Purpose: To investigate change in body function, activity, participation and other health related factors in women with CLBP after 13 years and to identify prognostic factors for pain, activity limitation and work ability.

Methods: In the present study, all women (n = 131) who were included in the cross-sectional study in 2006 and who were followed-up after 2 years are now invited to the same study-protocol 13 years after the first examination in 2006.

The Swedish Ethical Review Authority approved the study. Dnr: 2019-01944, 2019-05-21.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Background: Low back pain (LBP) is among the main causes of long-term sickness absence and is associated with considerable costs for both the individual and society. LBP affects 60-80% of the population and most individuals recover, while about 10-20% develop persistent pain and disability. Women have a higher risk of developing chronic LBP (CLBP) and widespread pain.

How LBP develops into recurrent and or more persistent pain with disability is not fully understood. Prognostic factors for pain development, work ability and self-rated activity limitation in 1 and 2-year follow-ups of persons with CLBP who sought primary care are described. Performance on physical capacity tests (6-min walking test), limitations on self-rated activity and participation and psycho-social factors play a role in unfavorable pain and function development. However, there are patients with CLBP who have no anatomical, demographic or psychosocial explanation of their symptoms. Some people with CLBP also have widespread pain and show altered pain sensitivity as fibromyalgia.

Purpose:To investigate change in body function, activity, participation and other health related factors in women with CLBP after 13 years and to identify prognostic factors for pain, activity limitation and work ability.

Methods: In the present study, all women (n = 131) who were included in the cross-sectional study in 2006 and who were followed-up after 2 years are now invited to the same study-protocol 13 years after the first examination in 2006.

Participants will be assessed by a registered physiotherapist at one occasion. Demographic data are collected, Questions about social support, sleep quality and sleep quantity, smoking and alcohol consumption. Self-reported questionnaires, pain and function performance tests will be assessed.

Data Analysis: Descriptive analysis based on data level; mean value (standard deviation), median (25th; 75th percentile), number and proportion will be used to present the group's characteristics. For analysis of change between the first assessment and after 13 years, Wilcoxon's signed rank test will be used for continuous variables and Teckentest / McNemar's test will be used for nominal data.

Multivariable regression analysis will be performed to calculate predictors of pain intensity (VAS), number of pain locations/pain distribution, self-rated activity limitation (RMDQ) and work ability after 13 years. Independent variables will be variables at the first assessment within the domains; body function (pain intensity, pain distribution, pain sensitivity, anxiety, depression, function test and stress), activity (RMDQ) and participation (work ability), as well as other health-related factors (Health-Related Quality of Life (SF-36), Leisure Time Physical Activity Instrument, Experience of Physical Activity). Multivariable regression models will be adjusted for age, level of education and social status. P-value is set to 0.05.

Ethical approval: The Swedish Ethical Review Authority approved the study. Dnr: 2019-01944, 2019-05-21.

Expected Results: The results is expected to provide knowledge about long-term clinical course (13 years) and prognostic factors for a positive pain and function development of CLBP in women seeking primary care.

Studietyp

Observationell

Inskrivning (Faktisk)

87

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Sverige
    • Sweden
      • Alingsås, Sweden, Sverige
        • Närhälsan, Region Västra Götaland
      • Borås, Sweden, Sverige
        • R&D primary care, Region Västra Götaland
      • Uddevalla, Sweden, Sverige
        • Närhälsan, Region Västra Götaland

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The 183 women who fulfilled the inclusion criteria were invited to participate in the cross-sectional study in 2006 and 131 accepted participation. All 131 from the cross-sectional study are now invited to participate in the present 13-year follow-up.The inclusion criteria at the first assessment in 2006 were: female patient, age between 18 and 60 years, low back pain (pain between costal margins and gluteal folds) with or without referred leg pain. Further criteria were; greater than 12-week's duration of symptoms, not pregnant, no known spinal disorders, no other severe somatic or psychiatric disorders, understanding in Swedish.

Beskrivning

Inclusion Criteria:

  • All participants (n=131) included in the Cross Sectional Study in 2006

Exclusion Criteria:

  • Pregnant
  • Serious somatic disorders
  • Serious psychiatric disorders

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: Kohort
  • Tidsperspektiv: Blivande

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
131 participants with chronic low back pain
All the participants (n=131) with chronic low back pain (CLBP) from the cross-sectional study in 2006 are invited to participate in the present 13-year follow-up. The same examination battery used in the cross-sectional study plus a supplementary Chair Stand Test will be used.
Övrig: Change in function, activity, participation and other health related factors in CLBP and to identify predictors for pain, activity and work ability after 13 years.
13-year prospective longitudinal cohort study

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Activity limitation
Tidsram: 2019, change from the first assessment (2006) to the present 13-year follow-up (2019), identify predictors (2006) for activity limitation (RMDQ) at the 13-year follow-up
Roland and Morris Disability Questionnaire (RMDQ) will be used.
2019, change from the first assessment (2006) to the present 13-year follow-up (2019), identify predictors (2006) for activity limitation (RMDQ) at the 13-year follow-up
Pain intensity
Tidsram: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019), identify predictors (2006) for pain intensity (VAS) at the 13-year follow-up.
A Visual Analogue Scale (VAS), ranging 0 to 100 mm will be used for pain intensity during the last week. 0 mm indicates no pain and 100 mm indicates very severe pain. Higher score indicates more severe pain.
2019, Change from the first assessment (2006) to the present 13-year follow-up (2019), identify predictors (2006) for pain intensity (VAS) at the 13-year follow-up.
Work ability
Tidsram: 2019, Comparison from the first assessment (2006) to the present 13-year follow-up (2019), identify predictors (2006) for work ability at the 13-year follow-up.
Sick-leave periods, and sickness and activity compensation is obtained from the Swedish Social Insurance Agency's MiDAS database. Self-reported work status dichotomized into two categories, work ability or not will be used.
2019, Comparison from the first assessment (2006) to the present 13-year follow-up (2019), identify predictors (2006) for work ability at the 13-year follow-up.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pain distribution
Tidsram: 2019, Comparison from the first assessment (2006) to the present 13-year follow-up (2019), identify predictors (2006) for pain distribution at the 13-year follow-up.
A drawing of the body will be used for assessing distribution of pain
2019, Comparison from the first assessment (2006) to the present 13-year follow-up (2019), identify predictors (2006) for pain distribution at the 13-year follow-up.

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Walking capacity
Tidsram: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
The 6-minute walk test (6MWT) will be used. The person walks back and forth in a measured distance of 30 meters for 6 minutes. The number of meters achieved is recorded.
2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Lower limb muscle endurance and muscle strength
Tidsram: 2019
The Chair Stand Test (CST) will be used.
2019
Hand grip strength
Tidsram: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
The Grippit®, electronic hand strength measurement will be used. Sustained hand grip strength will be measured during 10 seconds for each hand.
2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Hand grip strength
Tidsram: 2019
The Jamar Hand Dynamometer®, will be used for measuring hand grip strength for each hand.
2019
Pain sensitivity/pain threshold
Tidsram: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Somedic algometer® will be used.
2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Fatigue
Tidsram: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Multidimensional Fatigue Inventory (MFI-20) will be used.
2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
General fatigue
Tidsram: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
A Visual Analogue Scale (VAS), ranging 0 to 100 mm will be used for general fatigue during the last week. 0 mm indicates no tiredness and 100 mm indicates very tired. Higher score indicates more severe general fatigue.
2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Sleep quantity
Tidsram: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
One question will be used: "Do you think you get enough sleep?" (Range 1-4). Higher score indicate better sleep quantity.
2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Sleep quality
Tidsram: Time frame: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019)
One questions will be used: "On the whole, how do you think you sleep?" (Range 1-4). Higher score indicate better sleep quality.
Time frame: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019)
Social support
Tidsram: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
The 4-item version of Medical Outcome Study Social Support Survey will be used.
2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Stress
Tidsram: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Stress and Crisis Inventory (SCI-93) will be used for measuring clinical symptoms of stress.
2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Physical function
Tidsram: 2019, Comparison from the first assessment (2006) to the present 13-year follow-up (2019).
The Patient Specific Functional Scale (PSFS), will be used for the participant´s self-identified activities that are difficult to perform due to low back pain. Then the participant rates the level of difficulty for each identified activity on an 11-point numeric scale ranging from 0 ("unable to perform activity") to 10 ("able to perform activity unhindered or at pre-injury level").
2019, Comparison from the first assessment (2006) to the present 13-year follow-up (2019).
Leisure Time Physical Activity
Tidsram: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Leisure Time Physical Activity Instrument (LTPAI) will be used to assess the amount of self-rated physical activity in free time during a typical week
2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Experience of physical activity
Tidsram: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Experience of physical activity questionnaire will be used.
2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Risk for long-term disability and sick-leave
Tidsram: 2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Örebro Musculoskeletal Pain Screening Questionnaire (ÖMPSQ), estimate the risk for long-term disability and sick-leave. The sum score of 21 items will be used.
2019, Change from the first assessment (2006) to the present 13-year follow-up (2019).
Health-related quality of life
Tidsram: Change from the first assessment (2006) to the present 13-year follow-up (2019).
Short Form-36 (SF-36) will be used to measure health-related quality of life.
Change from the first assessment (2006) to the present 13-year follow-up (2019).
Alcohol consumption
Tidsram: Comparison from the first assessment (2006) to the present 13-year follow-up (2019).
The Alcohol Use Disorders Identification Test (Audit-C) will be used.
Comparison from the first assessment (2006) to the present 13-year follow-up (2019).

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Vastra Gotaland Region

Samarbetspartners

Göteborg University

Utredare

  • Huvudutredare: Lena Nordeman, PhD, R&D primary care Region Västra Götaland, University of Gothenburg Sweden

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 juni 2019

Primärt slutförande (Faktisk)

31 mars 2020

Avslutad studie (Faktisk)

31 mars 2020

Studieregistreringsdatum

Först inskickad

27 maj 2019

Först inskickad som uppfyllde QC-kriterierna

31 maj 2019

Första postat (Faktisk)

4 juni 2019

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

28 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

25 maj 2026

Senast verifierad

1 mars 2025

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • VGFOUREG855601

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera